These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 10205605)
21. [Effect of air humidity on traditional Chinese medicine extract of spray drying process and prediction of its powder stability]. He Y; Xie Y; Zheng LJ; Liu W; Rao XY; Luo XJ Zhongguo Zhong Yao Za Zhi; 2015 Feb; 40(3):424-9. PubMed ID: 26084164 [TBL] [Abstract][Full Text] [Related]
22. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders. Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252 [TBL] [Abstract][Full Text] [Related]
23. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler. Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178 [TBL] [Abstract][Full Text] [Related]
24. Liposomal dry powders as aerosols for pulmonary delivery of proteins. Lu D; Hickey AJ AAPS PharmSciTech; 2005 Dec; 6(4):E641-8. PubMed ID: 16408866 [TBL] [Abstract][Full Text] [Related]
25. The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler. Parumasivam T; Leung SS; Tang P; Mauro C; Britton W; Chan HK AAPS J; 2017 Jan; 19(1):191-202. PubMed ID: 27679516 [TBL] [Abstract][Full Text] [Related]
26. Effect of moisture content, temperature and exposure time on the physical stability of chitosan powder and tablets. Viljoen JM; Steenekamp JH; Marais AF; Kotzé AF Drug Dev Ind Pharm; 2014 Jun; 40(6):730-42. PubMed ID: 23596972 [TBL] [Abstract][Full Text] [Related]
27. Suitability of differently formulated dry powder Newcastle disease vaccines for mass vaccination of poultry. Huyge K; Van Reeth K; De Beer T; Landman WJ; van Eck JH; Remon JP; Vervaet C Eur J Pharm Biopharm; 2012 Apr; 80(3):649-56. PubMed ID: 22155763 [TBL] [Abstract][Full Text] [Related]
28. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler. Kaialy W; Momin MN; Ticehurst MD; Murphy J; Nokhodchi A Colloids Surf B Biointerfaces; 2010 Sep; 79(2):345-56. PubMed ID: 20537870 [TBL] [Abstract][Full Text] [Related]
29. Dry powder inhalers for pulmonary drug delivery. Frijlink HW; De Boer AH Expert Opin Drug Deliv; 2004 Nov; 1(1):67-86. PubMed ID: 16296721 [TBL] [Abstract][Full Text] [Related]
30. Effect of relative humidity on the electrostatic charge properties of dry powder inhaler aerosols. Kwok PC; Chan HK Pharm Res; 2008 Feb; 25(2):277-88. PubMed ID: 17619997 [TBL] [Abstract][Full Text] [Related]
31. In vitro deposition of the respirable fraction of dry powder inhalations determined by laser diffractometry and inertial impaction. Marques HM; Schmidt PC Pharmazie; 2002 Aug; 57(8):546-51. PubMed ID: 12227195 [TBL] [Abstract][Full Text] [Related]
32. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Coates MS; Chan HK; Fletcher DF; Chiou H Pharm Res; 2007 Aug; 24(8):1450-6. PubMed ID: 17404813 [TBL] [Abstract][Full Text] [Related]
33. Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols. Chew NY; Chan HK Pharm Res; 1999 Jul; 16(7):1098-103. PubMed ID: 10450937 [TBL] [Abstract][Full Text] [Related]
34. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Coates MS; Chan HK; Fletcher DF; Raper JA Pharm Res; 2005 Sep; 22(9):1445-53. PubMed ID: 16132356 [TBL] [Abstract][Full Text] [Related]
35. Importance of powder residence time for the aerosol delivery performance of a commercial dry powder inhaler Aerolizer(®). Jiang L; Tang Y; Zhang H; Lu X; Chen X; Zhu J J Aerosol Med Pulm Drug Deliv; 2012 Oct; 25(5):265-79. PubMed ID: 22280548 [TBL] [Abstract][Full Text] [Related]
36. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device. Fyrnys B; Stang N; Wolf-Heuss E Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S7-11. PubMed ID: 11385814 [TBL] [Abstract][Full Text] [Related]
37. Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler. Kemp JP; Hill MR; Vaughan LM; Meltzer EO; Welch MJ; Ostrom NK Ann Allergy Asthma Immunol; 1997 Oct; 79(4):322-6. PubMed ID: 9357377 [TBL] [Abstract][Full Text] [Related]
38. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. Feddah MR; Brown KF; Gipps EM; Davies NM J Pharm Pharm Sci; 2000; 3(3):318-24. PubMed ID: 11177650 [TBL] [Abstract][Full Text] [Related]
39. The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses. Coates MS; Fletcher DF; Chan HK; Raper JA Pharm Res; 2005 Jun; 22(6):923-32. PubMed ID: 15948036 [TBL] [Abstract][Full Text] [Related]
40. Use of an impinging jet for dispersion of dry powder inhalation aerosols. Wang Z; Lange CF; Finlay WH Int J Pharm; 2004 May; 275(1-2):123-31. PubMed ID: 15081143 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]